Skip to main navigation Skip to search Skip to main content

Phase II evaluation of LY156758 in metastatic breast cancer

Research output: Contribution to journalArticlepeer-review

Abstract

Fourteen patients with disseminated breast cancer with primary or secondary resistance to tamoxifen were treated with LY156758. There were no complete or partial responses and 1 patient showed a minor response. These data illustrate that LY156758 did not have significant antitumor activity in patients previously treated with tamoxifen therapy.

Original languageEnglish (US)
Pages (from-to)344-345
Number of pages2
JournalOncology (Switzerland)
Volume45
Issue number5
DOIs
StatePublished - 1988

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Phase II evaluation of LY156758 in metastatic breast cancer'. Together they form a unique fingerprint.

Cite this